Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2022-08-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
监事会关于公司计提减值准备事项合理性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board (监事会) of a company regarding the reasonableness of impairment provisions made in the 2022 half-year period. It references compliance with accounting standards and stock exchange listing rules, and confirms the appropriateness of the impairment provision. The document is very short (396 characters) and serves as an explanatory note or certification rather than a full financial report. It does not contain detailed financial data or comprehensive analysis. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not an audit report or management report. The document is essentially a regulatory or compliance statement related to accounting treatment, fitting best under Regulatory Filings (RNS).
2022-08-25 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by the independent directors regarding the use of company funds by controlling shareholders and related parties, as well as external guarantees during the reporting period (January 1 to June 30, 2022). It references regulatory guidelines and provides a detailed review and opinion on these specific issues. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a general regulatory filing or announcement. It is a standalone audit-related statement focusing on compliance and internal controls related to funds and guarantees, which fits the definition of an Audit Report / Information (AR). The document length is short (1081 characters), but it contains substantive content and independent directors' opinions, not just an announcement or certification. Therefore, the best classification is AR with high confidence. H1 2022
2022-08-25 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from a company's board of directors. It details the convening and attendance of the board meeting, the approval of the 2022 half-year report, and voting results. It does not contain the actual half-year financial report or detailed financial data but references the report published elsewhere. The document is short (656 characters) and serves as an announcement of the board meeting decisions, not the report itself. Therefore, it fits the category of Board/Management Information (MANG).
2022-08-25 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled as the company's 2022 semi-annual report (半年度报告), covering the period from January 1, 2022 to June 30, 2022. It contains detailed financial data, management discussion and analysis, company overview, business segments, product information, financial metrics, and risk disclosures. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. It is not an announcement or a brief summary, nor is it a certification or a regulatory filing. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-25 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) for the company 赛隆药业集团股份有限公司. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, total assets, and shareholder information. The document explicitly states it is a summary of the half-year report and includes substantive financial data and analysis for the period. The length is 2619 characters, which is typical for a summary but still contains actual financial figures and company performance metrics. This matches the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains actual financial statements and analysis. It is not merely an announcement or a certification, nor is it a full annual report or other filing type. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2022
2022-08-25 Chinese
关于全资子公司获得《药品补充申请批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving approval from the National Medical Products Administration for a drug supplement application. It details the drug information, approval details, and risk warnings. The document is short (1103 characters) and is an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not an annual or interim report, earnings release, or any form of shareholder meeting material. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval that does not fit other specific categories.
2022-07-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.